Revolution Medicines said daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a phase 3 pancreatic cancer study. The company plans to seek FDA approval for the KRAS-targeting pill.
Daraxonrasib showed median overall survival of 13.2 months versus 6.7 months for chemotherapy in a Phase III trial in previously treated metastatic pancreatic adenocarcinoma. The once-daily pan-RAS(ON) inhibitor was generally well tolerated, and the company plans to seek FDA approval.
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
Artificial intelligence is advancing cancer care through early detection tools and improved clinical trial predictions. A Carnegie Mellon spinout is developing AI to identify high-risk patients, while predictive analytics are helping pharmaceutical companies prioritize promising compounds in oncology trials.
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587827 |
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07409272 |
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT07262567 |
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07122466 |
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy |
ACTIVE_NOT_RECRUITING | |
| NCT07026916 |
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer |
WITHDRAWN | PHASE2 |
| NCT06967233 |
Multimodal Managements for Metastatic Pancreatic Cancer. |
COMPLETED | |
| NCT06951997 |
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer |
RECRUITING | PHASE2 |
| NCT06861088 |
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT06843551 |
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation |
RECRUITING | PHASE2 |
| NCT06782555 |
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab |
RECRUITING | PHASE1/PHASE2 |
